You are here:Home-Research Areas-Metabolic Disorder-Diabetes

Request The Product List ofDiabetes Diabetes

Cat. No. Product Name CAS No. Information
PC-62464

O-304

1261289-04-6

O-304 is a small molecule AMPK activator and PCSK9 modulator, reduces extracellular and secreted PCSK9 levels in human liver cells and reduces PCSK9 plasma levels and total cholesterol levels in obese rats.

Diabetes

Phase 2 Clinical

PC-61879

MK-0941 mesylate

1137916-97-2

MK-0941 mesylate (MK0941) is a novel potent, orally active Glucokinase (GK) activator with EC50 of 0.240 and 0.065 uM in 2.5 and 10 mM glucose, respectively; increases insulin secretion by 17-fold and glucose uptake up to 18-fold, respectively, in isolated rat islets of Langerhans and hepatocytes at 10 uM; exhibits strong glucose-lowering activity in rodent models of type 2 diabetes and healthy dogs.

Diabetes

Phase 2 Discontinued

PC-61878

MK-0941

752240-01-0

MK-0941 (MK0941) is a novel potent, orally active Glucokinase (GK) activator with EC50 of 0.240 and 0.065 uM in 2.5 and 10 mM glucose, respectively; increases insulin secretion by 17-fold and glucose uptake up to 18-fold, respectively, in isolated rat islets of Langerhans and hepatocytes at 10 uM; exhibits strong glucose-lowering activity in rodent models of type 2 diabetes and healthy dogs.

Diabetes

Phase 2 Discontinued

PC-61492

BMS-823778

1140898-87-8

BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2; exhibits robust acute pharmacodynamic effects in cynomolgus monkeys (ED50=0.6mg/Kg) and in diet-induced obese (DIO) mice (ED50=34 mg/Kg), also showed excellent inhibition in an ex vivo adipose DIO mouse model (ED50=5.2 mg/Kg).

Diabetes

Phase 2 Clinical

PC-61451

Mizagliflozin

666843-10-3

Mizagliflozin (DSP-3235, KGA-3235, GSK-1614235) is a potent, selective, orally active SGLT1 inhibitor with Ki of 27 nM, displays >350-fold selectivity over SGLT2; increases stool frequency and loosens stool consistency in phase I study; increases fecal wet weight in a dog model of loperamide-induced constipation and a rat model of low-fiber-diet-induced constipation, similar to lubiprostone.

Diabetes

Phase 1 Clinical

PC-61316

Teglicar

250694-07-6

Teglicar (ST-1326) is a potent, selective and reversible inhibitor of liver carnitine palmitoyl-transferase 1 (L-CPT1) with IC50 of 0.68 uM, Ki of 0.36 uM; displays an extraordinarily high selectivity (39-fold) toward the liver isoform over the heart isoform (muscle-CPT1;M-CPT1); reduces gluconeogenesis and improves glucose homeostasis, shows antiketotic and antidiabetic activity in diabetic db/db mice; also inhibits fatty acid oxidation associated with cell growth arrest, mitochondrial damage, and apoptosis induction in leukemia cell lines; orally active.

Diabetes

Phase 2 Discontinued

PC-61236

AGI-1067

216167-82-7

AGI-1067 (Succinobucol) is a potent inhibitor of TNF-α-inducible expression of VCAM-1, MCP-1 and E-selectin (IC50=6,10 and 25 uM) with concurrent antioxidant and lipid-modulating properties; inhibits atherosclerosis in LDL receptor-deficient and apolipoprotein E-deficient mice, also reduces VCAM-1 and MCP-1 mRNA levels in lungs of LPS-stimulated mice; inhibits atherosclerosis not only via its lipid-lowering effects but also by having direct anti-inflammatory effects on the vessel wall.

Diabetes

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com